Evidence map›Paper›PMID 40471316›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2025

Longitude characterization of immune-fibroblast axis following myocardial infarction via molecular imaging integrated with proteomics in minipigs.

Yaqi Zheng, Hongxing Wei, Yi Tian, Mingkai Yun, Tiantian Mou, Yao Lu, Jing Tian, Jingjing Meng, Yuetao Wang, Marcus Hacker and 4 more

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Yaqi Zheng *Department of Nuclear Medicine, Molecular Imaging Lab, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.
Hongxing WeiDepartment of Nuclear Medicine, Fu Wai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Yi TianDepartment of Nuclear Medicine, Molecular Imaging Lab, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.
Mingkai YunDepartment of Nuclear Medicine, Molecular Imaging Lab, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.
Tiantian MouDepartment of Nuclear Medicine, Molecular Imaging Lab, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.
Yao LuDepartment of Nuclear Medicine, Molecular Imaging Lab, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.
Jing TianDepartment of Nuclear Medicine, Molecular Imaging Lab, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.
Jingjing MengDepartment of Nuclear Medicine, Molecular Imaging Lab, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.
Yuetao WangDepartment of Nuclear Medicine, Institute of Clinical Translation of Nuclear Medicine and Molecular Imaging, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, China.
Marcus HackerDivision of Nuclear Medicine, Department of Biomedical Imaging and Image-guided Therapy, Vienna General Hospital, Medical University of Vienna, Vienna, Austria.
Wenli ChengDepartment of Hypertension, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.
Sijin LiDepartment of Nuclear Medicine, First Hospital of Shanxi Medical University, Taiyuan, Shanxi, China.
Xiaoli ZhangDepartment of Nuclear Medicine, Molecular Imaging Lab, Beijing Anzhen Hospital, Capital Medical University, Beijing, China. xlzhang68@126.com.ORCID 0000-0002-0770-5594
Xiang Li *Department of Nuclear Medicine, Molecular Imaging Lab, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.

Funding

Beijing Municipal Administration of Hospitals ZYLX202110National Natural Science Foundation of China 82171994Natural Science Foundation of Beijing Municipality 7232040
6 · The paper itself

Abstract

backgroundTargeting dynamic inflammatory-fibrotic pathways post-myocardial infarction (MI) is essential for exploring novel biomarkers to improve healing and attenuate adverse left ventricular (LV) remodeling. This study aimed to investigate the spatiotemporal dynamic pattern of immune inflammation and fibroblast activation and to map the proteomic profile of different regions over time after acute MI (AMI).

methodsIn 14 minipigs model of AMI, serial

resultsAl

conclusionsThis study revealed the spatio-temporal dynamic pattern of immune inflammation and fibroblast activation during the healing process following AMI. It provides a theoretical basis for future directions of molecular inflammatory combined fibroblast imaging-guided therapy post-MI.

Indexed as

FibroblastsMolecular ImagingMyocardial InfarctionProteomicsAnimalsFluorodeoxyglucose F18MalePositron Emission Tomography Computed TomographySwineSwine, MiniatureFluorodeoxyglucose F18Acute myocardial infarctionFibroblast activationImmune inflammationMolecular imagingProteomics

Identifiers

PMID40471316

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.